世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

制吐剤の市場規模、シェア、動向分析レポート:薬剤タイプ別(セロトニン受容体拮抗薬、ドパミン受容体拮抗薬)、用途別、最終用途別、地域別、セグメント別予測、2024年~2030年


Antiemetics Drugs Market Size, Share & Trends Analysis Report By Drug Type (Serotonin-receptor Antagonists, Dopamine Receptor Antagonists), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

制吐剤市場の成長と動向 Grand View Research, Inc.の最新レポートによると、制吐剤の世界市場規模は、2024年から2030年にかけて年平均成長率5.98%を示し、2030年までに112億米ドルに達する見込みです。吐き気... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Grand View Research
グランドビューリサーチ
2023年12月11日 US$5,950
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
150 英語

1~3営業日


 

サマリー

制吐剤市場の成長と動向

Grand View Research, Inc.の最新レポートによると、制吐剤の世界市場規模は、2024年から2030年にかけて年平均成長率5.98%を示し、2030年までに112億米ドルに達する見込みです。吐き気や嘔吐を引き起こす様々な疾患の有病率の増加と相まって、主要企業の戦略的イニシアチブの増加などの要因が、市場の需要を促進している。

主要な業界プレイヤーの活動の高まりは、制吐剤の需要を強化する主な要因の1つです。業界参加者は、制吐剤市場での地位を強化するために、提携、買収、新製品の発売、製品の承認、事業拡大など様々な取り組みを行っている。例えば、2020年5月、米国食品医薬品局は、化学療法によって誘発される吐き気と嘔吐の予防を目的としたヘルシン・グループのAKYNZEO注射剤を承認した。このように、新規製品の承認の増加は、今後数年間の業界の成長を促進すると予想される。

化学療法や術後の悪心・嘔吐(PONV)といった主な適応症に加え、食中毒や飲酒といった他の症状も、予測期間中、これらの医薬品の需要を牽引している。NCBIが2021年11月に発表した論文によると、サブサリチル酸ビスマスなどの特定の市販制吐薬は、食中毒に伴う吐き気や嘔吐に有効であることが示唆されている。

さらに、2022年10月にFrontiers誌に掲載された研究では、セロトニン受容体拮抗薬であるオンダンセトロンが、早期発症アルコール依存症(EOA)患者におけるアルコール使用障害に有効な治療薬であることが報告された。その結果、制吐薬の需要は、アルコール消費の増加や食中毒の発生に対応して増加すると予想される。

制吐薬市場レポートハイライト

- 薬剤の種類別では、セロトニン受容体拮抗薬セグメントが2023年に29.71%で市場を支配しており、この優位性は、セロトニン受容体拮抗薬の使用の増加と相まって癌の症例が増加していることに起因している。

- 用途別では、化学療法に伴う悪心・嘔吐をターゲットとした製品の上市が増加していることから、化学療法分野が2023年に45.70%のシェアを占め、市場最大の収益貢献者となった。

- 最終用途セグメントでは、小売薬局セグメントが2023年に47.91%の収益シェアで市場を支配した。対照的に、その他のセグメントは予測期間中に最速の成長を記録すると予測されている。

- 北米地域は、Pfizer、Merck Co & Inc、GSK plcのような大手企業の存在により、2023年に36.52%のシェアで市場を支配した。一方、アジア太平洋地域は予測期間中に最も速い成長を示すと予想される。

ページTOPに戻る


目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Segment Definitions
1.1.1. Drug Type Segment
1.1.2. Application Segment
1.1.3. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
1.12. Research Assumptions
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Target Diseases
3.2.1.2. Rising Investments by Industry Participants in R&D Activities
3.2.2. Market Restraint Analysis
3.2.2.1. Adverse Effects Associated with Anti emetics Drugs
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Drug Type Business Analysis
4.1. Antiemetics Drugs Market: Drug Type Movement Analysis
4.2. Serotonin-Receptor Antagonists
4.2.1. Serotonin-Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.3. Anticholinergics
4.3.1. Anticholinergics Market, 2018 - 2030 (USD Million)
4.4. Dopamine Receptor Antagonists
4.4.1. Dopamine Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.5. Neurokinin Receptor Antagonists
4.5.1. Neurokinin Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Other Drug Types Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Antiemetics Drugs Market: Application Movement Analysis
5.2. Chemotherapy
5.2.1. Chemotherapy Market, 2018 - 2030 (USD Million)
5.3. Gastroenteritis
5.3.1. Gastroenteritis Market, 2018 - 2030 (USD Million)
5.4. Post-Operative Surgery
5.4.1. Post Operative Surgery Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. End-use Business Analysis
6.1. Antiemetics Drugs Market: End-use Movement Analysis
6.2. Hospital & Clinics
6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Other End-use Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Antiemetics Drugs Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Argentina Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Antiemetics Drugs Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. Pfizer Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Cipla Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Merck KGaA
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Eagle Pharmaceuticals, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Johnson & Johnson Services, Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. GSK plc.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Astellas Pharma Inc.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. GLENMARK PHARMACEUTICALS LTD.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Viatris Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Baxter
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

 

ページTOPに戻る


 

Summary

Antiemetics Drugs Market Growth & Trends

The global antiemetics drugs market size is expected to reach USD 11.20 billion by 2030, exhibiting a CAGR of 5.98% from 2024 to 2030, according to a new report by Grand View Research, Inc. Factors such as the increasing strategic initiatives of the key players coupled with the increasing prevalence of various diseases causing nausea and vomiting are propelling market demand forward.

The rising activity of major industry players is one of the major factors bolstering the demand for antiemetics drugs. Industry participants are undertaking various initiatives such as partnerships, acquisitions, new product launches, product approvals, and expansions to strengthen their position in the antiemetics drugs market. For instance, in May 2020, the U.S. Food and Drug Administration approved an AKYNZEO injection from the Helsinn Group for the prevention of nausea and vomiting induced by chemotherapy. Thus, increasing novel product approvals are anticipated to drive industry growth in the coming years.

In addition to key indications such as chemotherapy and postoperative nausea and vomiting (PONV), other conditions such as food poisoning and alcohol consumption are also driving the demand for these medicines over the forecast period. An article published by NCBI in November 2021 suggests that certain over-the-counter antiemetics, such as Bismuth Subsalicylate, are effective in addressing nausea and vomiting associated with food poisoning.

Moreover, a study published in Frontiers in October 2022 reported that ondansetron, a serotonin receptor antagonist, is an effective treatment for alcohol use disorder in patients with early onset alcoholism (EOA). Consequently, the demand for antiemetic medicines is expected to rise in response to increased alcohol consumption and incidents of food poisoning.

Antiemetics Drugs Market Report Highlights

• On the basis of drug type, the serotonin-receptor antagonists segment dominated the market at 29.71% in 2023 and this dominance can be attributed to the rising cases of cancer coupled with the increasing use of serotonin-receptor antagonist drugs.

• Based on the application, the chemotherapy segment was the largest revenue contributor to the market with a share of 45.70% in 2023 owing to the increasing product launches targeting nausea and vomiting associated with chemotherapy.

• In the end-use segment, the retail pharmacy segment dominated the market with a revenue share of 47.91% in 2023. In contrast, the other segment is anticipated to register the fastest growth over the forecast period.

• The North America region dominated the market with a share of 36.52% in 2023 owing to the presence of major players like Pfizer, Merck Co & Inc, and GSK plc. On the other hand, Asia Pacific is expected to showcase the fastest growth over the forecast period.



ページTOPに戻る


Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Segment Definitions
1.1.1. Drug Type Segment
1.1.2. Application Segment
1.1.3. End-use Segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
1.12. Research Assumptions
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Prevalence of Target Diseases
3.2.1.2. Rising Investments by Industry Participants in R&D Activities
3.2.2. Market Restraint Analysis
3.2.2.1. Adverse Effects Associated with Anti emetics Drugs
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Drug Type Business Analysis
4.1. Antiemetics Drugs Market: Drug Type Movement Analysis
4.2. Serotonin-Receptor Antagonists
4.2.1. Serotonin-Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.3. Anticholinergics
4.3.1. Anticholinergics Market, 2018 - 2030 (USD Million)
4.4. Dopamine Receptor Antagonists
4.4.1. Dopamine Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.5. Neurokinin Receptor Antagonists
4.5.1. Neurokinin Receptor Antagonists Market, 2018 - 2030 (USD Million)
4.6. Others
4.6.1. Other Drug Types Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Antiemetics Drugs Market: Application Movement Analysis
5.2. Chemotherapy
5.2.1. Chemotherapy Market, 2018 - 2030 (USD Million)
5.3. Gastroenteritis
5.3.1. Gastroenteritis Market, 2018 - 2030 (USD Million)
5.4. Post-Operative Surgery
5.4.1. Post Operative Surgery Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. End-use Business Analysis
6.1. Antiemetics Drugs Market: End-use Movement Analysis
6.2. Hospital & Clinics
6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million)
6.3. Retail Pharmacy
6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
6.4. Others
6.4.1. Other End-use Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Antiemetics Drugs Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Denmark Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Sweden Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Norway Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Argentina Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Antiemetics Drugs Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Antiemetics Drugs Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. Pfizer Inc.
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Cipla Inc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Merck KGaA
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Eagle Pharmaceuticals, Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Johnson & Johnson Services, Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. GSK plc.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Astellas Pharma Inc.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. GLENMARK PHARMACEUTICALS LTD.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Viatris Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Baxter
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(中枢神経系作用薬)の最新刊レポート

本レポートと同じKEY WORD(dopamine receptor)の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Grand View Research社はどのような調査会社ですか?


グランドビューリサーチ(Grand View Research)は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/05 10:26

153.43 円

167.28 円

201.52 円

ページTOPに戻る